
    
      A Pivotal Phase 1, Randomized, Single-Dose, 4-Period, Crossover Relative Bioavailability
      Study of 2 doses of 3.5mgMELT-100, IV Midazolam, and IV Ketamine 18mg under Fasted Conditions
      in Healthy Volunteers
    
  